Global Biosimilar Contract Manufacturing Market 2023-2029

March 2023 | 71 pages | ID: G515E23FB7A8EN
Gen Consulting Company

Abstracts

According to the latest data, the market size of the global biosimilar contract manufacturing sector is expected to rise by USD 4.3 billion with a CAGR of 15.9% by the end of 2029. Biosimilar contract manufacturing refers to the process of outsourcing the production of biosimilar drugs to a third-party manufacturer. Biosimilar drugs are biologic medications that are highly similar to already approved biologic drugs, but are offered at a lower cost. Biosimilar contract manufacturing involves the transfer of manufacturing technology and expertise from the originator company to the contract manufacturer. The contract manufacturer uses their facilities and resources to produce the biosimilar drug under strict quality control guidelines. The contract manufacturer is responsible for ensuring that the biosimilar drug meets the same standards for safety, efficacy, and quality as the originator drug. Biosimilar contract manufacturing helps to reduce the cost of producing biosimilar drugs, increase manufacturing capacity, and improve access to affordable biologic medications.Biosimilar contract manufacturing refers to the process of outsourcing the production of biosimilar drugs to a third-party manufacturer. Biosimilar drugs are biologic medications that are highly similar to already approved biologic drugs, but are offered at a lower cost. Biosimilar contract manufacturing involves the transfer of manufacturing technology and expertise from the originator company to the contract manufacturer. The contract manufacturer uses their facilities and resources to produce the biosimilar drug under strict quality control guidelines. The contract manufacturer is responsible for ensuring that the biosimilar drug meets the same standards for safety, efficacy, and quality as the originator drug. Biosimilar contract manufacturing helps to reduce the cost of producing biosimilar drugs, increase manufacturing capacity, and improve access to affordable biologic medications.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global biosimilar contract manufacturing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the source, scale of operation, product, indication, and region. The global market for biosimilar contract manufacturing can be segmented by source: mammalian, non-mammalian. The mammalian segment is estimated to account for the largest share of the global biosimilar contract manufacturing market. Biosimilar contract manufacturing market is further segmented by scale of operation: commercial, research. The commercial segment held the largest revenue share in 2022. Based on product, the biosimilar contract manufacturing market is segmented into: finished dosage forms (FDF), active pharmaceutical ingredients (APIs). Globally, the finished dosage forms (FDF) segment made up the largest share of the biosimilar contract manufacturing market. On the basis of indication, the biosimilar contract manufacturing market also can be divided into: oncology, blood disorders, inflammatory and autoimmune diseases, others. The oncology segment was the largest contributor to the global biosimilar contract manufacturing market in 2022. Biosimilar contract manufacturing market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.

Market Segmentation
By source: mammalian, non-mammalian
By scale of operation: commercial, research
By product: finished dosage forms (FDF), active pharmaceutical ingredients (APIs)
By indication: oncology, blood disorders, inflammatory and autoimmune diseases, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global biosimilar contract manufacturing market with some of the key players being Lonza Group AG, Boehringer Ingelheim GmbH, FUJIFILM Diosynth Biotechnologies USA Inc., Catalent Inc, Samsung Biologics Co., Ltd., AbbVie, Inc., Emergent BioSolutions Inc., Merck KGaA, Pfizer Inc., Wuxi Biologics Cayman Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global biosimilar contract manufacturing market.
To classify and forecast the global biosimilar contract manufacturing market based on source, scale of operation, product, indication, region.
To identify drivers and challenges for the global biosimilar contract manufacturing market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biosimilar contract manufacturing market.
To identify and analyze the profile of leading players operating in the global biosimilar contract manufacturing market.

Why Choose This Report
Gain a reliable outlook of the global biosimilar contract manufacturing market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY SOURCE

Mammalian
Non-mammalian

PART 6. MARKET BREAKDOWN BY SCALE OF OPERATION

Commercial
Research

PART 7. MARKET BREAKDOWN BY PRODUCT

Finished dosage forms (FDF)
Active pharmaceutical ingredients (APIs)

PART 8. MARKET BREAKDOWN BY INDICATION

Oncology
Blood disorders
Inflammatory and autoimmune diseases
Others

PART 9. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 10. KEY COMPANIES

Lonza Group AG
Boehringer Ingelheim GmbH
FUJIFILM Diosynth Biotechnologies USA Inc.
Catalent Inc
Samsung Biologics Co., Ltd.
AbbVie, Inc.
Emergent BioSolutions Inc.
Merck KGaA
Pfizer Inc.
Wuxi Biologics Cayman Inc.

DISCLAIMER